• Enhancing Cell-Based Assays: 3-hydroxybutyrate (BHBA) Soluti

  2026-06-30

  Discover how 3-hydroxybutyrate (BHBA, SKU M1297) addresses reproducibility, mechanistic clarity, and workflow reliability in cell viability, proliferation, and cytotoxicity assays. This article delivers scenario-driven guidance and protocol insights, helping life science researchers leverage BHBA's signaling and epigenetic properties for robust metabolic and neuroprotection studies.

• GSTA1 Exacerbates Oxidative Stress in α-Amanitin Hepatotoxic

  2026-06-29

  This study uncovers a paradoxical role for GSTA1 in worsening α-amanitin-induced liver injury by depleting glutathione and intensifying oxidative stress. The mechanistic insight that GSTA1 can switch from detoxifier to a contributor of hepatotoxicity has implications for both mechanistic toxicology and therapeutic targeting.

• FH1 Small Molecule (B3700): Redefining Hepatocyte Maturity i

  2026-06-29

  Explore how FH1, a primary small molecule for cultured hepatocyte function enhancement, drives unprecedented iPS cell differentiation and functional maturity. This article uniquely integrates optogenetic gene regulation and assay optimization for advanced liver cell model development.

• PK/PD Evaluation of Cefazedone in Community-Acquired Pneumon

  2026-06-28

  This article reviews a clinical pharmacokinetic and pharmacodynamic study of intravenous Cefazedone (Refosporen) for mild to moderate community-acquired pneumonia (CAP). The findings clarify optimal dosing, demonstrate robust efficacy against susceptible bacteria, and inform translational research and laboratory workflows.

• Plk1-Mediated Regulation of p31comet and Mitotic Checkpoint

  2026-06-27

  This study delineates how Polo-like kinase 1 (Plk1) phosphorylates p31comet, thereby suppressing its ability to promote Mitotic Checkpoint Complex (MCC) disassembly with TRIP13. The findings provide mechanistic insight into the regulation of mitotic exit, with implications for cell cycle research and targeted disruption of chromosome segregation in cancer biology.

• Metoprolol: Selective Beta1-Adrenoceptor Antagonist Workflow

  2026-06-26

  Metoprolol’s unique selectivity enables precise dissection of beta1-adrenergic signaling in cardiovascular, inflammation, and cancer models. This article provides advanced protocol guidance, troubleshooting tips, and practical workflow enhancements using Metoprolol from APExBIO, leveraging recent pharmacokinetic insights to elevate research reproducibility.

• NF 449: Precision Purinergic Receptor Antagonist for Platele

  2026-06-26

  NF 449 stands out as a nanomolar-potency, subtype-selective purinergic receptor antagonist, enabling unprecedented precision in dissecting platelet activation and aggregation pathways. Its superior selectivity for P2X1 positions it as a gold-standard tool for antithrombotic agent research and functional platelet assays.

• A1 vs. AMD3100: New Advances in CXCR4 Inhibition for Colorec

  2026-06-25

  Khorramdelazad et al. introduce A1, a fluorinated small-molecule CXCR4 inhibitor, as a novel candidate for colorectal cancer therapy. The study demonstrates A1’s superior inhibition of tumor growth and immune modulation compared to AMD3100, highlighting important implications for future cancer metastasis research and targeted treatment strategies.

• Trelagliptin Succinate: Reliable Assays for Diabetes Researc

  2026-06-25

  This article addresses critical laboratory challenges in diabetes mellitus research, focusing on the evidence-based use of Trelagliptin succinate (SKU A3889) for robust cell-based assays. It provides scenario-driven guidance on protocol optimization, data interpretation, and product selection to enhance reproducibility and assay performance.

• Myeloid S100A8/A9 Drives Hypertrophy-to-Heart Failure Transi

  2026-06-24

  This study uncovers S100A8/A9 in myeloid cells as a critical regulator of the progression from adaptive cardiac hypertrophy to heart failure under pressure overload. Single-cell RNA sequencing and targeted knockout models reveal S100A8/A9’s mechanistic role in orchestrating immune cell-driven inflammation and fibrotic remodeling, highlighting it as a therapeutic target and offering new insight into precise molecular interventions.

• Stiripentol: Next-Gen LDH Inhibitor for Epilepsy & Lactate M

  2026-06-23

  Stiripentol is a novel, noncompetitive LDH inhibitor validated for epilepsy research and astrocyte-neuron lactate shuttle modulation. Its chemical distinctiveness expands experimental options for Dravet syndrome models and immunometabolic studies. Stringent protocol parameters and cross-domain findings support its reproducibility and utility.

• Tumor-Targeted PAD4 Inhibition: Suppressing NETs and Metasta

  2026-06-23

  This study introduces meta-phenylboronic acid-modified PAD4 inhibitors, exemplified by Compound 5i TFA, which achieve highly selective tumor targeting and inhibit the PAD4-H3cit-NETs pathway in neutrophils. These findings provide a new approach to limiting tumor growth and metastasis while minimizing off-target toxicity.

• Phenothiazines Drive Macrophage Antibacterial Defense via RO

  2026-06-22

  The reference study demonstrates that phenothiazines, including promethazine hydrochloride, significantly enhance the antibacterial capacity of macrophages through induction of reactive oxygen species (ROS) and autophagy. These findings clarify host-directed mechanisms for controlling intracellular pathogens and offer new directions for immunological and inflammation research.

• Antipyrine in Predictive BBB Modeling: Next-Gen Pharmacokine

  2026-06-22

  Explore how Antipyrine (1,5-dimethyl-2-phenylpyrazol-3-one) drives advances in predictive blood-brain barrier modeling and pharmacokinetic studies. This in-depth review reveals practical assay strategies and novel insights beyond conventional pain and fever research.

• Gramine Induces Ferroptosis via CUL3–MTDH Axis in TNBC Model

  2026-06-21

  The referenced study demonstrates that Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) selectively suppresses triple-negative breast cancer (TNBC) by triggering ferroptosis through a CUL3-mediated ubiquitination pathway targeting MTDH. These mechanistic insights broaden understanding of ferroptosis regulation and suggest Gramine as a precise research tool in cancer biology.

466 records 14/32 page Previous Next First page 上5页 1112131415 下5页 Last page